FGF23 and the parathyroid glands

被引：0
作者：
Justin Silver
Tally Naveh-Many
机构：
[1] Hadassah Hebrew University Medical Center,Minerva Center for Calcium and Bone Metabolism, Nephrology Services
来源：
Pediatric Nephrology | 2010年 / 25卷
关键词：
Calcium; FGF23; Klotho; Phosphate; PTH;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fibroblast growth factor 23 (FGF23) is a phosphatonin that is secreted by osteocytes and osteoblasts in response to hyperphosphatemia and 1,25-dihydroxyvitamin D (1,25D). It acts on its receptor complex, Klotho–FGFR1c (fibroblast growth factor receptor 1 c-splicing form), in the distal convoluted tubule to repress renal phosphorus reabsorption in the proximal tubule and suppress the renal synthesis of 1,25D. Klotho–FGFR1c is also expressed in the parathyroid glands. FGF23 acts on the receptor complex in the parathyroid glands to decrease parathyroid hormone (PTH) gene expression and PTH secretion through activation of the MAPK pathway. In chronic kidney disease (CKD), both FGF23 and PTH are increased, implying resistance of the parathyroid glands to FGF23. There is a decrease in the Klotho–FGFR1c complex in the parathyroid glands in both experimental CKD and in patients with end-stage renal disease. In addition, in advanced experimental CKD, FGF23 has a decreased ability to inhibit PTH expression.
引用
收藏
页码：2241 / 2245
页数：4
相关论文
共 266 条
  • [1] Feng JQ(2006)Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism Nat Genet 38 1310-1315
  • [2] Ward LM(2009)Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease Bone 45 1161-1168
  • [3] Liu S(2009)Do osteocytes contribute to phosphate homeostasis? Curr Opin Nephrol Hypertens 18 285-291
  • [4] Lu Y(2002)Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo Endocrinology 143 3179-3182
  • [5] Xie Y(2000)Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 Nat Genet 26 345-348
  • [6] Yuan B(2008)Endocrine functions of bone in mineral metabolism regulation J Clin Invest 118 3820-3828
  • [7] Yu X(2010)Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active J Clin Endocrinol Metab 95 578-585
  • [8] Rauch F(2008)Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis N Engl J Med 359 584-592
  • [9] Davis SI(2009)High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients Nephrol Dial Transplant 24 2792-2796
  • [10] Zhang S(2006)Regulation of fibroblast growth factor-23 signaling by klotho J Biol Chem 281 6120-6123
12345678910